Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)

A Contract Award Notice
by NHS ENGLAND

Source: Find a Tender
Type: Contract (Services)
Duration: 8.5 year (est.)
Value: £12M

Sector: HEALTH
Published: 16 Jan 2026
Delivery: To 16 Sep 2034 (est.)
Deadline: n/a

Related Terms

Location

London

Geochart for 2 buyers and 12 suppliers

2 buyers

NHS England London

12 suppliers

University College London Hospitals NHS Trust London
Guys & St Thomas NHS Trust London
Barts Health NHS Trust London
Royal Marsden NHS Trust London
Cambridge University Hospitals NHS Trust Cambridge
Oxford University Hospitals NHS FT Oxford
University Hospitals Southampton Southampton
University Hospitals Bristol & Weston NHS Trust Bristol
Leicester NHS Trust University Hospitals Leicester
Newcastle Upon Tyne Hospitals NHS Trust Newcastle upon Tyne
Christie NHS Trust Manchester
Clatterbridge Cancer Centre NHS Trust Wirral

Description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive TherapyUnit (ITU).Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752The treatment is complex to administer, requiring surgical expertise for tumourresection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:Lot 1: LondonLot 2: East of EnglandLot 3: South EastLot 4: South WestLot 5: MidlandsLot 6: North East and YorkshireLot 7: North WestThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots.The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Lot Division

1	London NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. … 7: North WestThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.As a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London. The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
2	East of England NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. … 7: North WestThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England.The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
3	South East NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. … 7: North WestThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East.The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
4	South West NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. … 7: North WestThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West.The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
5	Midlands NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. … 7: North WestThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands.The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
6	North East & Yorkshire NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. … 7: North WestThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire.The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
7	North West NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. … 7: North WestThis process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West.The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Award Detail

1	University College London Hospitals NHS Trust (London) Num offers: 4 Value: £11,876,000
2	Guys & St Thomas NHS Trust (London) Num offers: 4 Value: £11,876,000
3	Barts Health NHS Trust (London) Num offers: 4 Value: £11,876,000
4	Royal Marsden NHS Trust (London) Num offers: 4 Value: £11,876,000
5	Cambridge University Hospitals NHS Trust (Cambridge) Num offers: 1 Value: £11,876,000
6	Oxford University Hospitals NHS FT (Oxford) Num offers: 2 Value: £11,876,000
7	University Hospitals Southampton (Southampton) Num offers: 2 Value: £11,876,000
8	University Hospitals Bristol & Weston NHS Trust (Bristol) Num offers: 2 Value: £11,876,000
9	Leicester NHS Trust University Hospitals (Leicester) Num offers: 3 Value: £11,876,000
10	Newcastle Upon Tyne Hospitals NHS Trust (Newcastle upon Tyne) Num offers: 2 Value: £11,876,000
11	Christie NHS Trust (Manchester) Num offers: 2 Value: £11,876,000
12	Clatterbridge Cancer Centre NHS Trust (Wirral) Num offers: 2 Value: £11,876,000

Renewal Options

Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Award Criteria

Quality & innovation	50.0
Value	2.0
Integration, Collaboration & Service Sustainability	21.0
Improving Access, Reducing Health Inequalities and Facilitating Choice	17.0
Social Value	10.0
Not Applicable	_

CPV Codes

85100000 - Health services

Indicators

Options are available.
Award on basis of price and quality.

Other Information

This is a Provider Selection Regime(PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by Wednesday 28th January 2026. Representations should be sent to jessica.gaucher-thompson@nhs.net. The award decision-makers are NHS England National Commissioning Group (NCG).These contracts have not yet formally been awarded; this notice serves as an intention to award under the PSR.The Key Criteria used for the award:Quality & innovation: 50%Value: 2%Integration, Collaboration & Service Sustainability: 21%Improving Access, Reducing Health Inequalities and Facilitating Choice: 17%Social Value: 10%.The rationale for selecting the provider(s) was based on them meeting all mandatory requirements and achieving the minimum quality threshold set out in the procurement documentation. This decision has been made as per NHS England governance processes, by the National Commissioning Group on 16th December 2025. No conflicts of Interest were identified amongst decision-makers.

Reference

FTS 003869-2026